Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
GHENT, Belgium, Jan. 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday 14 January 2016 at 10:30 a.m. Pacific Standard Time (07:30 p.m. Central Eastern Time).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx. The presentation will provide an overview of the major achievements in 2015 as well as an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for 2016.
The presentation will be webcast live and can be accessed on the day via this link. A replay of the webcast will be available on the Company's website, under the news & events section, for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
Pdf version of the press release http://hugin.info/137912/R/1976678/723490.pdf
HUG#1976678
